IRIS
NICOLINI, LAURA AMBRA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 6.506
AS - Asia 88
SA - Sud America 15
NA - Nord America 2
AF - Africa 1
Totale 6.612
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 6.500
CN - Cina 60
VN - Vietnam 15
BR - Brasile 10
SG - Singapore 9
AR - Argentina 2
EC - Ecuador 2
ES - Italia 2
ID - Indonesia 2
US - Stati Uniti d'America 2
UZ - Uzbekistan 2
CI - Costa d'Avorio 1
GB - Regno Unito 1
NL - Olanda 1
PY - Paraguay 1
RU - Federazione Russa 1
SK - Slovacchia (Repubblica Slovacca) 1
Totale 6.612
Salva come PNG Salva come JPEG
Città #
Genova 3.356
Genoa 1.915
Rapallo 621
Vado Ligure 577
Beijing 29
Bordighera 27
Ho Chi Minh City 7
Singapore 4
Tianjin 3
Hanoi 2
Rio de Janeiro 2
Verona 2
Abidjan 1
Ashburn 1
Asunción 1
Birmingham 1
Biên Hòa 1
Brumadinho 1
Cachoeiro de Itapemirim 1
Cajamar 1
Curitiba 1
Goiânia 1
Gresik 1
Hải Dương 1
Jakarta 1
Jizzakh 1
Moscow 1
Niterói 1
Nové Mesto nad Váhom 1
Quito 1
Reconquista 1
Sousa 1
Tailândia 1
Tashkent 1
Villa Ángela 1
Vinh 1
Totale 6.569
Salva come PNG Salva come JPEG
Nome #
Clinical characteristics, management and in-hospital mortality of patients with COVID-19 In Genoa, Italy 270
Budget impact analysis of sofosbuvir-based regimens for the treatment of HIV/HCV-coinfected patients in northern Italy: A multicenter regional simulation 198
Epidemiological and clinical features of hepatitis delta in HBsAg-positive patients by HIV status. 183
Evaluation of insulin resistance in a cohort of HIV-infected youth. 178
Implementing TB control in a rural, resource-limited setting: The stop-TB Italia project in Senegal 167
Effectiveness of a project to prevent HIV vertical transmission in the Republic of Congo. 164
Bronchoalveolar lavage fluid characteristics and outcomes of invasively mechanically ventilated patients with COVID-19 pneumonia in Genoa, Italy 162
Cost per care of the first year of direct antiviral agents in the liguria region: A multicenter analysis 155
Hepatitis B reactivation in HBsAg-negative/HBcAb-positive allogeneic haematopoietic stem cell transplant recipients: risk factors and outcome. 152
Impact of a mixed educational and semi-restrictive antimicrobial stewardship project in a large teaching hospital in Northern Italy 152
Prevalence and Clinical Significance of Persistent Viral Shedding in Hospitalized Adult Patients with SARS-CoV-2 Infection: A Prospective Observational Study 149
Hepatitis B Virus Vaccination in HIV: Immunogenicity and Persistence of Seroprotection up to 7 Years Following a Primary Immunization Course 146
Liver Enzyme Elevation During Darunavir-Based Antiretroviral Treatment in HIV-1-Infected Patients With or Without Hepatitis C Coinfection: Data from the ICONA Foundation Cohort. 144
Efficacy of lamivudine prophylaxis in preventing hepatitis B virus reactivation in patients with resolved infection undergoing allogeneic SCT and receiving rituximab 141
Current status of newer carbapenems 140
Coinfection with HIV and hepatitis C virus in 229 children and young adults living in Europe 139
Undetectable HCV-RNA at treatment-week 8 results in high-sustained virological response in HCV G1 treatment-experienced patients with advanced liver disease: The International Italian/Spanish Boceprevir/Peginterferon/Ribavirin Name Patients Program 136
Trend of estimated glomerular filtration rate during ombistasvir/paritaprevir/ritonavir plus dasabuvir ± ribavirin in HIV/HCV co-infected patients 136
A global view to HBV chronic infection: Evolving strategies for diagnosis, treatment and prevention in immunocompetent individuals 133
Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: Results from a large observational cohort study (SCOLTA) 130
Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens? 128
Successful recovery of associated interstitial nephritis and focal segmental glomerulosclerosis in patients with HCV and HIV treated with sofosbuvir and daclatasvir and revision of literature 128
Control of the HIV-1 DNA reservoir is associated in vivo and in vitro with NKp46/NKp30 (CD335 CD337) inducibility and interferon gamma production by transcriptionally unique NK cells 125
HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels 125
Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies 125
Correction to: Impact of a mixed educational and semi-restrictive antimicrobial stewardship project in a large teaching hospital in Northern Italy (Infection, 10.1007/s15010-017-1063-7) 125
Nevirapine-based regimens in routine clinical settings: results from a large Italian cohort of HIV-1 infected adults. 123
Tigecycline use in serious nosocomial infections: a drug use evaluation. 123
Visceral leishmaniasis in hematopoietic cell transplantation: Case report and review of the literature 122
Weight gain: A possible side effect of all antiretrovirals 122
Tocilizumab and steroid treatment in patients with COVID-19 pneumonia 119
Role of [18F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography for Diagnosis and Treatment of Sarcoidosis in an HIV-2-Infected Patient. 117
Management of chronic viral hepatitis in the hematological patient 114
Ligurian Vaccination in HIV Program (LIV in HIV): the experience of Genoa metropolitan area 113
Co-administration of tenofovir plus protease inhibitor based antiretroviral therapy during sofosbuvir/ledipasvir treatment for HCV infection: Much Ado About Nothing? 111
CD8+CD28-CD127loCD39+Treg Expansion: a New Pathogenic Mechanism for HIV Infection? 108
Hepatitis C virus RNA levels at week-2 of telaprevir/boceprevir administration are predictive of virological outcome 106
Improvement of ALT decay kinetics by all-oral HCV treatment: Role of NS5A inhibitors and differences with IFN-based regimens 105
Genetic polymorphisms of IL28b gene as predictors of response to dual therapy in genotypes 1 and 4-HCV and HIV/HCV-infected patients 103
Optimal efficacy of interferon-free HCV retreatment after protease inhibitor failure in real life 99
Drug treatment for multidrug-resistant Acinetobacter baumannii infections 98
Incidence of candidaemia and relationship with flucanazole use in an intensive care unit 97
Pegylated interferon α plus ribavirin for the treatment of chronic hepatitis C: A multicentre independent study supported by the Italian Drug Agency 93
Therapeutic management of chronic hepatitis B in clinical Practice: a region-wide survey. 83
Long course of daptomycin in the treatment of meticillin-resistant Staphylococcus epidermis endocarditis and spondylodiscitis 82
Rs12979860 and rs8099917 single nucleotide polymorphisms of interleukin-28B gene: simultaneous genotyping in caucasian patients infected with hepatitis C virus. 81
Fulminant Hepatitis Associated with Echovirus 25 during Treatment with Ocrelizumab for Multiple Sclerosis 81
The efficacy of the new anti HCV therapy, implementation of a path based on the logic of micro-elimination in the Department of Mental Health and Addictions ASL4 Chiavarese 76
Barriers to HCV micro-elimination in a cohort of people living with HIV (PLWH) 71
Comments on “Real-world re-treatment outcomes of direct-acting antiviral therapy failure in patients with chronic hepatitis C” 70
Insights on common vaccinations in HIV-infection: efficacy and safety 65
Phalangeal quantitative ultrasound: cheaper methods for screening and follow-up of bone pathologies in HIV-infected women? 59
Effectiveness of first-generation HCV protease inhibitors: does HIV coinfection still play a role? 57
Prevalence and Risk Factors for Significant Liver Fibrosis in Patients with HIV Infection 50
Neutralizing monoclonal antibodies for the prevention of severe COVID-19: a retrospective study during Omicron BA.1 variant surge 48
HCV treatment in children and young adults with HIV/HCV co-infection in Europe 48
Ten Years of Medical Informatics and Standards Support for Clinical Research in an Infectious Diseases Network 45
Efficacy, safety and feasibility of treatment of chronic HCV infection with directly acting agents in hematopoietic stem cell transplant recipients – Study of infectious diseases working party of EBMT 36
null 31
Totale 6.787
Salva come PNG Salva come JPEG
Categoria #
all - tutte 24.402
article - articoli 23.776
book - libri 0
conference - conferenze 626
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 48.804
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021366 0 0 0 0 48 30 46 63 28 66 31 54
2021/2022629 28 19 34 78 25 62 23 140 54 72 24 70
2022/2023743 68 65 6 77 97 106 9 50 112 57 88 8
2023/2024430 12 51 5 50 36 92 36 34 25 8 38 43
2024/20251.378 30 91 27 122 190 150 143 229 60 56 119 161
2025/2026721 261 56 205 131 68 0 0 0 0 0 0 0
Totale 6.787